BAC
Bank of America Corporation
BAC has the edge over NEWT overall, supported by stronger fundamentals and stronger modeled upside.
NEWT
NewtekOne, Inc.
NEWT offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
NEWT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| N/A | |
| N/A |
NEWT's revenue and profitability are currently stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like NEWT.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
NEWT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 5.2x | $10.44 | — |
| Cheap | 5.5x | $10.25 | -1.8% |
| Current | 5.6x | $10.44 | — |
| Fair | 7.1x | $13.41 | +28% |
| Expensive | 10x | $19.07 | +83% |
Historical ranges are pointers, not guarantees.
NEWT has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over NEWT on the outlook, with more favorable earnings and revenue expectations.
NEWT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Stable | |
| Stable | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NEWT's profitability to weaken, with its earnings and revenue holding steady. However, they disagree widely on these estimates.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
NEWT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.02 | +7.3% |
| Q3 2026 | $1.88 | -16% |
| Q2 2026 | $2.21 | +9.4% |
| Q1 2026 | $2.26 | +17% |
| Q4 2025 | $2.18 | +11% |
| Q3 2025 | $2.24 | +32% |
| Q2 2025 | $2.02 | +24% |
| Q1 2025 | $1.93 | +32% |
| Q4 2024 | $1.96 | +27% |
NEWT earned $1.88 per share over the past year, down 16% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over NEWT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
NEWT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $71.8M | -4.2% |
| Q2 2026 | $75.1M | +7% |
| Q1 2026 | $71M | +7% |
| Q4 2025 | $73.3M | -2.7% |
| Q3 2025 | $74.9M | +19% |
| Q2 2025 | $70.2M | +15% |
| Q1 2025 | $66.3M | +14% |
| Q4 2024 | $75.4M | +42% |
NEWT's revenue has held roughly level: $72M last quarter, down 4.2% from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over NEWT on cash generation, producing positive trailing cash flow while its opponent burns cash.
NEWT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$152.4M | +$14.9M |
| Q2 2026 | -$163.3M | +$36.6M |
| Q1 2026 | -$257.5M | -$196.8M |
| Q4 2025 | -$151.4M | -$59.8M |
| Q3 2025 | -$167.3M | -$141.4M |
| Q2 2025 | -$199.9M | -7108% |
| Q1 2025 | -$60.7M | -$22M |
| Q4 2024 | -$91.7M | -$39M |
NEWT's free cash flow was −$725M over the past year, against −$520M the year before. Free cash flow isn't a meaningful measure for financial services companies like NEWT.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over NEWT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
NEWT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +51K shares |
| 1 year | +10% | +2.7M shares |
| 3 years | +16% | +4M shares |
NEWT has 29M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $167,000 |
| Q3 2025 | — |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
NEWT Net Leverage
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
NEWT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.9 | Neutral |
| Stochastic | 2.7 | Oversold |
NEWT's weekly RSI is 36 (neutral) and its Stochastic is 3 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
NEWT PE vs Financial Services Sector
| Metric | NEWT | Sector median | Relative |
|---|---|---|---|
| PE | 5.6x | 13x | 57% below |
| PE % | 19 | 63 | 44 pts below |
NEWT has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has the edge over NEWT on trend strength, trading above more of its moving averages.
NEWT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 4.7% below |
| 20 week MA | $12.4 | 16% below |
| 50 week MA | $12.6 | 17% below |
| 100 week MA | $12.1 | 14% below |
| 200 week MA | $13.0 | 19% below |
NEWT is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
NEWT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.7 | $18.2 | -20% |
| 2021 | $18.2 | $27.9 | +54% |
| 2022 | $27.9 | $16.7 | -40% |
| 2023 | $16.7 | $13.8 | -17% |
| 2024 | $13.8 | $13.0 | -5.7% |
| 2025 | $13.0 | $11.5 | -12% |
| 2026 YTD | $11.5 | $10.4 | -9.1% |
NEWT has the edge over BAC on returns for 2026, with the stronger performance.